James Ballenger to Anti-Anxiety Agents
This is a "connection" page, showing publications James Ballenger has written about Anti-Anxiety Agents.
Connection Strength
0.892
-
Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. Psychol Med. 2003 Apr; 33(3):511-8.
Score: 0.198
-
Current treatments of the anxiety disorders in adults. Biol Psychiatry. 1999 Dec 01; 46(11):1579-94.
Score: 0.157
-
The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder. Adv Biochem Psychopharmacol. 1992; 47:431-47.
Score: 0.091
-
The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder. Psychopharmacol Bull. 1991; 27(2):171-9.
Score: 0.085
-
Efficacy of benzodiazepines in panic disorder and agoraphobia. J Psychiatr Res. 1990; 24 Suppl 2:15-25.
Score: 0.079
-
Recent advances in the psychopharmacological treatment of anxiety disorders. Hosp Community Psychiatry. 1988 Nov; 39(11):1157-65.
Score: 0.073
-
Pharmacotherapy of the panic disorders. J Clin Psychiatry. 1986 Jun; 47 Suppl:27-32.
Score: 0.062
-
Recognizing the patient with social anxiety disorder. Int Clin Psychopharmacol. 2000 Jul; 15 Suppl 1:S1-5.
Score: 0.041
-
Treatment of panic disorder in the general medical setting. J Psychosom Res. 1998 Jan; 44(1):5-15.
Score: 0.034
-
A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997; 58 Suppl 11:11-8.
Score: 0.032
-
Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995 Oct; 167(4):487-94.
Score: 0.029
-
Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol. 2002 Dec; 5(4):315-25.
Score: 0.012